1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Excessive Daytime Somnolence: new trials by email Literature Review of Excessive Daytime Somnolence trials Research Report on Excessive Daytime Somnolence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study Valiloxybate, Placebo - Parkinson Disease, Excessive Daytime Somnolence | Phase 2 | Withdrawn | XWPharma | 2021-11-01 | 2025-03-19 | |
| Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Caffeine 100-200 mg BID, placebo - Parkinson's Disease, Excessive Daytime Somnolence | Phase 2 / Phase 3 | Completed | Ron Postuma | 58 | 2007-04-01 | 2015-04-16 |
Disorders of Excessive Somnolence (2) · Parkinson Disease (2)
Basal Ganglia Diseases (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Dyssomnias (2) · Mental Disorders (2) · Movement Disorders (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Parkinsonian Disorders (2) · Sleep Disorders, Intrinsic (2) · Sleep Wake Disorders (2) · Synucleinopathies (2)
BID protein, human (1) · Caffeine (1)
Ron Postuma (1) · XWPharma (1)
Canada (1)